MetaVia Q2 FY26 net loss widens to $5.3 million
MTVA•Q2 loss widens as R&D spending rises
MetaVia posts Q2 net loss of $5.3 million, or $0.90 per share, widening from a $4 million loss a year earlier.
R&D expenses rise 52.17% to $3.48 million, driven by higher direct costs tied to DA-1726 development.
Total operating expenses climb 25.2% to $5.39 million, while G&A edges down 3.74% to $1.91 million.
Cash position and DA-1726 trial update
Cash and cash equivalents increase to $12.6 million as of June 30 from $10.3 million at Dec. 31; cash is seen funding operations through 2026.
All active patients reached 48 mg and 64 mg in DA-1726 Phase 1 Part 3; 16-week topline data is expected in Q4 2026.
